Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 9—September 2020

Risk-Based Estimate of Human Fungal Disease Burden, China

Ling-Hong Zhou1, Ying-Kui Jiang1, Ruo-Yu Li, Li-Ping Huang, Ching-Wan Yip, David W. Denning2, and Li-Ping Zhu2Comments to Author 
Author affiliations: Huashan Hospital, Shanghai, China; and Fudan University, Shanghai (L.-H. Zhou, Y.-K. Jiang, L.-P. Huang, C.-W. Yip, L.-P. Zhu); Peking University First Hospital, Beijing, China (R.-Y. Li); Peking University, Beijing (R.-Y. Li); National Clinical Research Center for Skin and Immune Diseases, Beijing (R.-Y. Li); Wythenshawe Hospital, Manchester, UK (D.W. Denning); University of Manchester, Manchester (D.W. Denning); Global Action Fund for Fungal Infections, Geneva, Switzerland (D.W. Denning)

Main Article

Table 3

Summary of fungal infection burden in China according to major risk factors*

Infection No. infections per underlying disorder per year
Total no. cases Rate/100,000 population
None HIV/AIDS Respiratory Cancer ICU
Candida peritonitis
ICU + surgery NE NE NE NE 8,939 8,939 0.62
Oral candidiasis NE 74,258 NE NE NE 74,258 5.18
Esophageal candidiasis NE 49,204 NE NE NE 49,204 3.43
Recurrent Candida vaginitis 29,082,000 NE NE NE NE 29,082,000 4,056.68†
IA NE 1,040 1,145,908 31,800 NE 1,178,748 82.21
CPA NE NE 488,716 NE NE 488,716 34.09
ABPA NE NE 1,237,797 NE NE 1,237,797 86.33
SAFS NE NE 1,633,892 NE NE 1,633,892 113.96
CM 26,249 13,086 NE 26,172 NE 65,607 4.57
PCP NE 18,482 NE 9,241 NE 27,723 1.93
Talaromycosis NE 4,951 NE NE NE 4,951 0.35
Mucormycosis 2,868 NE NE NE NE 2,868 0.20
Fungal keratitis 100,365 NE NE NE NE 100,365 7.00
Onychomycosis 37,278,384 NE NE NE NE 37,278,384 2,600.00
Total burden 66,490,604 161,021 4,506,313 132,822 25,341 71,316,101 7,002.32

*ABPA, allergic bronchopulmonary aspergillosis; ART, antiretroviral therapy; CAPD, continuous ambulatory peritoneal dialysis; CM, cryptococcal meningitis; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; ICU, intensive care unit; NE, no estimation could be made because of the lack of data; PCP, pneumocystis pneumonia; SAFS, severe asthma with fungal sensitization.
†Female population only.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

Page created: May 26, 2020
Page updated: August 18, 2020
Page reviewed: August 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.